CIT v. Sadan Vikas (India) Ltd.

335 ITR 117High Court2011#950 most cited

What is CIT v. Sadan Vikas (India) Ltd. authority for?

Weighted deduction under Section 35(2AB) is allowable for R&D expenditure incurred even if the approval from the DSIR is granted in a subsequent assessment year, provided the application for approval was made in time. The assessee is entitled to the deduction if the approval is based on verification of details submitted.

112

judgments rely on this decision, according to BharatTax’s citation analysis of 366,005 Indian tax judgments — from 2016 to 2025.

Also referred to as

CIT v. Sadan Vikas (India) Ltd. · Section 35(2AB) · weighted deduction · R&D expenditure · DSIR approval · scientific research expenditure · deduction allowed

Issues it is cited on

Judgments citing CIT v. Sadan Vikas (India) Ltd.

The ACIT, 5(1), Indore vs. M/S. Symbiotic Pharmalab Ltd., Indore

In the result, the appeal of the Revenue stands dismissed

ITA 373/IND/2016[2009-10]Status: DisposedITAT Indore10 Dec 2018AY 2009-10

Bench: Shri Kul Bharat & Shri Manish Boradassessment Year: 2009-10 Acit 5(1), M/S. Symbiotic Indore बनाम/ Pharmalab Ltd. 385, Vs. Pigdamber, Rau, Indore (Revenue) (Respondent) Pan: Aagcs9311 Revenue By Shri Ashima Gupta, Cit- Dr Respondent By Shri Ajay Tulsiyan & Kapil Shah, Cas Date Of Hearing: 29.11.2018 Date Of Pronouncement: 10.12.2018 आदेश / O R D E R Per Manish Borad, A.M: This Appeal Of Revenue Pertaining To A.Y. 2009-10 Is Directed Against The Order Of Ld. Commissioner Of Income Tax(Appeals)-Ii, Indore, (In Short ‘Cit(A)’), Dated 31.12.2015 Which Is Arising Out Of The Order U/S 143(3) Of The Income Tax Act 1961(Hereinafter Called As The ‘Act’) Framed On M/S. Symboitic Pharmalab Ltd. Itano.373/Ind/2016 05.12.2011 By Acit, 5(1) Indore. The Revenue Has Raised Following Grounds Of Appeal: “1. Whether The Ld. Cit(A) Has Erred In Law & On Facts In Restricting The Addition Of Rs. 2,60,50,027/- To Rs.3,74,195/- & Addition Made By The Ao 'After Disallowing U/S 35(2Ab) Deleted To The Extent Of Rs. 2,56,75,832/- On Account Of R&D Expenditure Without Appreciating The Fact That The Assessing Officer Had Pointed Out That Disr Has Not Issue Report In Form 3Cl To Dgit Exemption & Even When No Satisfactory Clarification Was Given By The Assessee To The Ao.” “2.Whether The Ld. Cit(A) Has Erred In Law & On Facts In Deleting The Disallowance Of Rs. 9,97,920/- Made By The Ao On Account Of Foreign Exchange Loss Without Appreciating The Fact That The Assessing Officer Had Pointed Out That The Loss Claimed By The Assessee In The Year Of Fluctuation In The Rate Of Exchange Or The Same Is Allowable Only In The Year' Of Repayment Of Such Loans.”

Section 143(2)Section 143(3)Section 14ASection 35

…has occurred”. Ld. AR also took us through the detailed paper book running from pages 1 to 313 and also placed reliance on the following judgments: 1. DCIT vs. Famy Care Ltd. in ITANo.1798/Mum/2013, I.T.A.T., Mumbai 2. CIT vs. Sandan Vikas (India) Ltd. (2011) 335 ITR 117 Hon'ble High Court of Delhi 3. CIT vs. Claris Lifesciences Ltd. (2010) 326 ITR 251, Hon'ble High Court of Gujarat 8. We have heard the rival contentions, perused the record placed before us and carefully gone through the judgments relied by the Ld. counsel for the assessee. 5 M/s. Symboitic Pharmalab Ltd. ITANo.373/Ind/2016 Ground No.1 “1. Wh…